Financial Highlights

During the three months ended June 30, 2026 (from April 1, 2026 to June 30, 2026), the Japanese economy remained on a gradual recovery trend, supported by improvements in the employment and income environment. Meanwhile, uncertainty continued in the global economy, as developments in trade policies, including US tariff policies, and the situation in the Middle East affected financial and capital markets and corporate activities.
In the fertility treatment field, in which the Kitazato Group operates, demand continued to expand both in Japan and overseas, driven by the trend toward later marriage and childbearing, as well as growing social awareness of fertility treatment. In Japan, the environment surrounding fertility treatment and related fields continued to improve, with an increase in the number of medical institutions providing assisted reproductive technology and the enhancement of public support, including subsidies for oocyte cryopreservation. Overseas, the fertility treatment market is also expected to expand over the medium to long term, driven by the enhancement of support programs and healthcare delivery systems.
Under these circumstances, the Kitazato Group worked to strengthen its overseas operating base, launch new and improved products, accumulate intellectual property, and enhance its production and supply systems. In June 2026, the Group announced a medium-term management plan positioned as the first stage of its long-term vision, “Kitazato Challenge 2036,” and is promoting initiatives aimed at achieving sustainable growth in existing businesses and building a foundation for future growth.
Effective July 1, 2026, the Company changed its Japanese corporate name. Under the new corporate name, the Group will work together to realize its corporate philosophy, “Happiness, for the Next Generations – Bringing Smiles to Future Generations.”
The Group’s consolidated financial results for the three months ended June 30, 2026 are as follows.

[Net sales]
The Group’s net sales for the three months ended June 30, 2026 amounted to ¥3,017 million, an increase of 24.0% year on year.
In Japan, in addition to stable growth in demand, one-off orders arose due to concerns over the impact of the situation in the Middle East. As a result, net sales amounted to ¥993 million (up 10.9% year on year).
Overseas, net sales amounted to ¥2,024 million (up 31.6% year on year), reflecting sales growth in Europe, the U.S., and other regions.
By product category, new products launched in the previous fiscal year contributed to sales growth in Media and Medical Device. Demand for Cryodevice remained firm both in Japan and overseas, while demand for Micro Tools remained robust mainly in Europe and the U.S. As a result, net sales in all product categories increased from the same period of the previous fiscal year.

[Profit]
Gross profit amounted to ¥1,886 million (up 20.2% year on year), mainly due to an increase in net sales, partly offset by an increase in the cost of sales ratio due to a change in the product mix.
Operating profit amounted to ¥1,517 million (up 27.0% year on year), reflecting an increase in gross profit and a year-on-year decrease in selling, general and administrative expenses.
Ordinary profit amounted to ¥1,535 million (up 36.5% year on year), reflecting foreign exchange gains and the absence of listing-related expenses recorded in the same period of the previous fiscal year.
As a result, profit attributable to owners of parent amounted to ¥1,007 million, an increase of 35.1% year on year.